Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Lynk Closes $16 Million C2 Round to Advance JAK Inhibitors for Autoimmune Diseases

publication date: Sep 21, 2023

Hangzhou Lynk Pharmaceuticals closed a $16 million Series C2 financing to advance its portfolio of oncology and autoimmune therapies. In May, the company raised $28 million in a Series C1 round. Lynk’s portfolio consists of highly selective second-gen and tissue-specific third-gen small molecule JAK inhibitors, which have shown quick onset and excellent efficacy, according to the company. Its lead drug, LNK01001, recently reported positive results in a Phase II trial for rheumatoid arthritis and other autoimmune diseases. The C2 round was led by Shaoxing Binhai New Area Biomedical Industry Equity Investment Fund. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital